INTUITIVE Q3 2026 EARNINGS RELEASE - INTUITIVE SURGICAL INC

Financial Performance:

• Q3 2026 revenue grew 22% to $3.04 billion, with 84% classified as recurring revenue.
• Non-GAAP net income per share (EPS) increased 25% to $3.00; Non-GAAP operating margin was 42% (41% excluding a one-time $28M tariff refund).
• Non-GAAP gross margin was 69.9% (68.9% excluding tariff refund), up 90 basis points year-over-year driven by cost reductions and fixed overhead leverage.
• DaVinci System placements (net) grew 40% to 546 units; Capital revenue grew 30% to $769 million, while Service revenue grew 22% to $482 million.
• GAAP net income was $523 million ($1.49/share), significantly impacted by a one-time $450 million litigation settlement expense.
• Cash position stood at $6.8 billion at quarter-end; operating cash flow was offset by $2.9 billion in share repurchases ($377 avg price) and $113 million in capital expenditures.

Guidance and Future Outlook:

• Full-year 2026 DaVinci procedure growth guidance narrowed to 14–15% (from 13.5–15.5%), with expectations near the midpoint.
• Non-GAAP gross margin guidance updated to 68.7–68.3% of revenue, incorporating an estimated 90 basis point impact from tariffs and refunds.
• 2026 Non-GAAP operating expense growth forecast at 11–13%, with R&D growth outpacing SG&A.
• 2026 Non-GAAP other income forecast at $300–310 million, reflecting lower cash balances post-share repurchases.
• Management expects the 3–5% revenue per procedure headwind from new pricing actions to be partially offset by mix shifts toward DaVinci 5, SinglePort, and force feedback adoption over 2027.
• Long-term strategy includes expanding the addressable market in benign procedures and international markets, with a new manufacturing facility planned for Penang, Malaysia, operational by 2028.

Business Segments and Product Lines:

• Total procedures grew 15%: DaVinci procedures up 14% (10% in US, 20% international) and Ion procedures up 31%.
• Installed base reached over 13,200 systems; DaVinci 5 accounted for 65% of global system placements and >25% of US procedures (up from 13% YoY).
• SinglePort (SP) procedures surged 55% (US +50%, Korea +40%), with the installed base reaching 487 units across 27 countries; a vessel sealer submission is planned for Q4 2026.
• New indications cleared: Force feedback instrumentation for cardiac on DaVinci 5 (EU) and transvaginal gynecological procedures on SP.
• Future pipeline includes ROSE (real-time cytology) and endobronchial ultrasound for Ion, plus hyperspectral imaging and AI features for DaVinci 5.
• Telepresence adoption is rising, serving as a foundation for telesurgery targeted for regulatory clearance in H1 2028.

Market and Competitive Landscape:

• US market: DaVinci 5 and SinglePort adoption is accelerating in benign general surgery and ASCs; 41% net system placements in US.
• International market: Europe (led by Germany +20% growth), Asia (India +42% procedures, Japan recovery), and Rest of World grew 20–22%.
• China: Operating environment remains challenging; revenue per procedure expected to drop due to government policy changes, though volume growth remains inline with corporate average.
• Competitive dynamics: Management remains confident in cart-based architecture over modular competitors in ASCs, citing superior ecosystem integration and training.
• Market expansion: Intuitive is elevating investment in Asia, entering new countries in 2027, and establishing local clinical/economic validation for benign procedures (e.g., hernia, cholecystectomy).

Risks and Challenges:

• Pricing headwinds: Extended Use Program (EUP) and China policy changes expected to reduce DaVinci I&A revenue per procedure by 3–5% once fully implemented.
• Regulatory delays: US clearance for extended use instruments and future AI/surgery capabilities requires regulatory confidence.
• Macro factors: Potential impacts from ACA enrollment changes, Medicaid eligibility shifts, and 340B policy changes in the US.
• Operational risks: Supply chain constraints, input cost inflation (freight, semiconductors), and uneven quarter-to-quarter placements in new geographies.
• Litigation: Final court approval for the $450M class action settlement regarding third-party remanufacturing is pending.

Management Commentary and Tone:

• Tone was confident and strategic, emphasizing "durable growth" driven by innovation and a focus on expanding the addressable market in benign procedures.
• Management framed pricing actions as a strategic reinvestment to broaden access rather than a concession, citing elasticity data from previous programs.
• CEO Dave Rosa highlighted the shift from anecdotal evidence to real-time customer dashboards validating clinical and economic superiority of robotics.
• CFO Jamie Samath emphasized the durability of the business model and the ability to offset pricing headwinds through cost reductions and premium product mix.
• CMO Dr. Jamie Wong presented the "Benign COMPARE" study to reinforce the value proposition for high-volume benign procedures.

Analyst Questions and Answers:

• US Procedure Growth: Analysts asked about a perceived slowdown in US DaVinci growth (10%); Management attributed this to high prior-year comps and confirmed that new capacity, ASC focus, and pricing actions will drive acceleration in 2027.
• Pricing & Elasticity: Questions on the EUP timeline and volume response; Management confirmed implementation starts H1 2027, expects modest gross margin impact offset by cost savings, and believes elasticity will drive volume growth in benign segments.
• ASCs & Competition: Analysts queried the ASC opportunity and modular competitors; Management reiterated belief in cart-based architecture and noted that ~70% of ASC volume is affiliated with existing IDNs they already serve.
• Force Feedback: Adoption currently at 8% of DaVinci 5 cases; Management cited surgeon data showing improved potency outcomes in prostatectomy as a key value driver.
• Margins: Analysts asked about operating margin trajectory; Management confirmed long-term target of 35–40% and intends to invest excess margin capacity in R&D and growth initiatives.

Other Key Points:

• Settlement reached with US customers regarding third-party instrument remanufacturing and servicing to provide certainty and maintain product safety focus.
• The "Benign COMPARE" study meta-analysis of 1.5 million DaVinci patients showed significantly lower conversion to open surgery (54% lower odds vs. laparoscopy) and shorter hospital stays.
• Revenue from DaVinci 5 and SP is growing faster than the base, providing natural offsets to the EUP pricing headwinds.
• Management plans to update the long-term soft tissue surgery opportunity estimate in January 2027.